Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Market value tracking: BioCryst Pharmaceuticals Inc.
BioCryst (BCRX) surrendered $6.75 (24 percent) to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury